title: Intravenous iron administration: new observations and time for the next steps.
abstract: In this issue of Kidney International, the Dialysis Outcomes and Practice Patterns Study reports that hemodialysis patients with monthly intravenous iron supplementation of 300-399 mg or ⩾400 mg had a 13 or 18% higher risk of dying, respectively, compared with those receiving 100-199 mg per month, with no obvious differences in cause-specific mortalities. This study supports that randomized controlled trials are urgently needed to identify optimized iron supplementation strategies for anemic dialysis patients.
authors.affiliation: Department of Internal Medicine VI, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Günter
authors.initials: G
authors.lastname: Weiss
authors.affiliation: Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Florian
authors.initials: F
authors.lastname: Kronenberg
mesh_terms: D005260:Female; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D006435:Renal Dialysis / Q000401:mortality*
chemical_list: D007501:Iron